A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF LEVOSIMENDAN IN PULMONARY HYPERTENSION PATIENTS WITH HEART FAILURE AND PRESERVED LEFT VENTRICULAR EJECTION FRACTION (PH-HFPEF): LEVEL: LEVOSIMENDAN TO IMPROVE EXERCISE LIMITATION IN PATIENTS WITH PH-HFPEF
- Registry ID
- TNX-103-06
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- TENAX THERAPEUTICS INC
- Start date
- 2025-02-21
- Last update
- 2024-02-27
Conditions
- PULMONARY HYPERTENSION
- HEART FAILURE WITH PRESERVED EJECTION FRACTION
Related clinical trials
- A PHASE 2A, OPEN-LABEL, SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF MARIDEBART CAFRAGLUTIDE ON MORTALITY AND
MORBIDITY IN PARTICIPANTS LIVING WITH HEART FAILURE WITH PRESERVED OR
MILDLY REDUCED EJECTION FRACTION AND OBESITY (MARITIME-HF)
- A PHASE 2, MULTICENTER, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE EFFECTS
OF SOTATERCEPT FOR THE TREATMENT OF COMBINED POSTCAPILLARY AND PRECAPILLARY
PULMONARY HYPERTENSION (CPC-PH) DUE TO HEART FAILURE WITH PRESERVED
EJECTION FRACTION (HFPEF)
- PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY AND
EFFICACY STUDY OF CDR132L ON REVERSE CARDIAC REMODELLING IN PARTICIPANTS WITH
HEART FAILURE WITH PRESERVED EJECTION FRACTION AND LEFT VENTRICULAR HYPERTROPHY
- A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND
SAFETY OF MOSLICIGUAT IN PARTICIPANTS WITH PULMONARY HYPERTENSION ASSOCIATED
WITH INTERSTITIAL LUNG DISEASE
- ATHENA: EFFECTS OF ZILTIVEKIMAB VERSUS PLACEBO ON HEART FAILURE SYMPTOMS AND PHYSICAL FONCTION I PATIENTS WITH HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION AND SYSTEMIC INFLAMMATION
View on source registry